Ronald G. Sibbald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ronald G. Sibbald has a total of 258 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth A. Ayello
To earn CME credit, you must read the CME article and complete the quiz online, answering at least 13 of the 18 questions correctly
7 shared publications- Douglas Queen
Medicalhelplines.com Inc Toronto Ontario Canada
6 shared publications - Kevin Y. Woo
Wound Healing Clinic, Women's College Hospital, Toronto, Ontario, Canada
6 shared publications Kevin Y. Woo
School of Nursing, Queen's University, Kingston, and Wound Care Consultant, West Park Health Centre, Toronto, Ontario, Canada
5 shared publicationsPatricia Coutts
5 shared publicationsAfsaneh Alavi
4 shared publications
Latest Publications
- 19 August 2026
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
Assessing Challenges and Barriers to Effective Wound Care in Rural Indigenous Communities
OBJECTIVE: To explore the lived experiences of patients with chronic wounds from a remote Indigenous community in Northern Manitoba, Canada, focusing on challenges in wound management, the impact on quality of life, barriers to wound care access, and the role of traditional healing practices. METHODS: A qualitative descriptive study was co-created with members of the Nisichawayasihk Cree Nation (NCN) and conducted in alignment with OCAP (Ownership, Control, Access, and Possession) principles. Fifteen participants with current or past chronic wounds participated in semi-structured, in-person interviews at the NCN Family and Community Wellness Centre in June 2024. Interviews were audio-recorded, transcribed verbatim, and analyzed inductively using NVivo to identify key thematic domains. RESULTS: Five thematic domains emerged: (1) access to health care—limited local services, long wait times, and substantial travel and financial burden to obtain specialty care; (2) inadequate wound care—inconsistent follow-up and reliance on self-management at home; (3) patient education—focused largely on diabetes control with little wound-specific guidance; (4) living with pain—persistent pain limiting mobility, sleep, and emotional well-being; and (5) traditional Indigenous medicine—frequent use of culturally rooted treatments, though often not acknowledged or integrated by Western providers. CONCLUSIONS: Indigenous patients experience major barriers to timely, effective wound care, driven by geographic isolation, fragmented services, and gaps in patient education. Integrating traditional healing with Western practice, strengthening community-based care pathways, and improving specialist access may support limb preservation, reduce preventable amputation, and enhance quality of life.
- 19 August 2026
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
Assessing Challenges and Barriers to Effective Wound Care in Rural Indigenous Communities
OBJECTIVE: To explore the lived experiences of patients with chronic wounds from a remote Indigenous community in Northern Manitoba, Canada, focusing on challenges in wound management, the impact on quality of life, barriers to wound care access, and the role of traditional healing practices. METHODS: A qualitative descriptive study was co-created with members of the Nisichawayasihk Cree Nation (NCN) and conducted in alignment with OCAP (Ownership, Control, Access, and Possession) principles. Fifteen participants with current or past chronic wounds participated in semi-structured, in-person interviews at the NCN Family and Community Wellness Centre in June 2024. Interviews were audio-recorded, transcribed verbatim, and analyzed inductively using NVivo to identify key thematic domains. RESULTS: Five thematic domains emerged: (1) access to health care—limited local services, long wait times, and substantial travel and financial burden to obtain specialty care; (2) inadequate wound care—inconsistent follow-up and reliance on self-management at home; (3) patient education—focused largely on diabetes control with little wound-specific guidance; (4) living with pain—persistent pain limiting mobility, sleep, and emotional well-being; and (5) traditional Indigenous medicine—frequent use of culturally rooted treatments, though often not acknowledged or integrated by Western providers. CONCLUSIONS: Indigenous patients experience major barriers to timely, effective wound care, driven by geographic isolation, fragmented services, and gaps in patient education. Integrating traditional healing with Western practice, strengthening community-based care pathways, and improving specialist access may support limb preservation, reduce preventable amputation, and enhance quality of life.
- 27 February 2026
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
- Vol. 39 (3) , 124-134
Diabetic Foot Infections: A Toolkit for Wound Care Clinicians
Diabetic foot infections (DFIs) are a serious complication of diabetes, leading to high rates of hospital admission, amputation, and early death—particularly in persons living in resource-limited communities. Although the updated International Working Group on the Diabetic Foot guidelines in 2024 provide well-laid-out strategies for managing DFIs, these tend to be better suited for use in well-resourced centers. This case-based review discusses and applies these guidelines for an approach to DFI in real-world scenarios. It focuses on supporting health care providers working in community and resource-limited settings. The review explores how to recognize and diagnose DFI, including the use of imaging modalities, and how to distinguish soft tissue infection from bone infection or noninfectious entities. Management strategies are detailed regarding antibiotic considerations and approaches, including in resource-limited settings, and when other interventions or surgical referral may be important. Practical clinical cases are used to illustrate key points, emphasizing how care may be adapted based on the context. The authors also consider health equity aspects by identifying barriers that may be faced by patients who are from racialized backgrounds and live in resource-limited settings. The review aims to equip frontline wound clinicians with a pragmatic approach to managing DFIs that is grounded in up-to-date evidence framed in a real-world context. JOURNAL/aswca/04.03/00129334-202604000-00004/figure1/v/2026-03-10T151712Z/r/image-jpeg GENERAL PURPOSE: To provide clinicians with an evidence-based approach to the diagnosis and management of diabetic foot infections (DFIs). TARGET AUDIENCE: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and registered nurses with an interest in skin and wound care. LEARNING OBJECTIVES/OUTCOMES: After participating in this educational activity, the participant will: Analyze evidence-based clinical and laboratory findings to accurately diagnose (DFIs) and diabetic foot osteomyelitis. Evaluate patient-specific clinical data to select evidence-based management strategies for patients with (DFIs) and diabetic foot osteomyelitis.
- 27 February 2026
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
- Vol. 39 (3) , 124-134
Diabetic Foot Infections: A Toolkit for Wound Care Clinicians
Diabetic foot infections (DFIs) are a serious complication of diabetes, leading to high rates of hospital admission, amputation, and early death—particularly in persons living in resource-limited communities. Although the updated International Working Group on the Diabetic Foot guidelines in 2024 provide well-laid-out strategies for managing DFIs, these tend to be better suited for use in well-resourced centers. This case-based review discusses and applies these guidelines for an approach to DFI in real-world scenarios. It focuses on supporting health care providers working in community and resource-limited settings. The review explores how to recognize and diagnose DFI, including the use of imaging modalities, and how to distinguish soft tissue infection from bone infection or noninfectious entities. Management strategies are detailed regarding antibiotic considerations and approaches, including in resource-limited settings, and when other interventions or surgical referral may be important. Practical clinical cases are used to illustrate key points, emphasizing how care may be adapted based on the context. The authors also consider health equity aspects by identifying barriers that may be faced by patients who are from racialized backgrounds and live in resource-limited settings. The review aims to equip frontline wound clinicians with a pragmatic approach to managing DFIs that is grounded in up-to-date evidence framed in a real-world context. JOURNAL/aswca/04.03/00129334-202604000-00004/figure1/v/2026-03-10T151712Z/r/image-jpeg GENERAL PURPOSE: To provide clinicians with an evidence-based approach to the diagnosis and management of diabetic foot infections (DFIs). TARGET AUDIENCE: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and registered nurses with an interest in skin and wound care. LEARNING OBJECTIVES/OUTCOMES: After participating in this educational activity, the participant will: Analyze evidence-based clinical and laboratory findings to accurately diagnose (DFIs) and diabetic foot osteomyelitis. Evaluate patient-specific clinical data to select evidence-based management strategies for patients with (DFIs) and diabetic foot osteomyelitis.
- Open Access
- 29 July 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (5) , 463-467
Serum Biomarkers in Bullous Pemphigoid: A Systematic Review
Introduction: Bullous pemphigoid (BP) is the most common type of subepidermal blistering disease, usually observed in the elderly population, with a mean age of presentation between 66 and 83 years. BP is a psychosocially ladened disease, with many patients experiencing negative body image, social isolation, and depression. The identification and validation of biomarkers in BP may further the understanding of disease pathogenesis, provide objective measures in assessing efficacy in clinical trials, and identify new targets for targeted therapy. Methods/Results: Two databases (Medline and Embase) were searched from database inception to September 2023. All published articles reporting on biomarker levels of BP patients in serum compared to healthy controls were included. A total of 877 unique articles were identified, resulting in the inclusion of 62 case-control studies reporting on a total of 1837 patients and 140 unique biomarkers. Biomarkers were categorized into T-cell mediated, B-cell mediated, innate immune system, and coagulation cascade pathway. The most notable biomarkers identified include increases in anti-BP180/230 immunoglobulin (Ig)G/E, total IgE, TNF-α, B-cell activating factor, interleukin-31, eosinophil cationic protein, MMP-9, and coagulation cascade biomarker levels. The results of this review provide the greatest support for a role of anti-BP180/230 autoantibodies, Th2 cells, eosinophils, and the coagulation cascade in the pathogenesis of BP. Conclusions: The pathogenesis of BP has an underlying autoimmune etiology centred around the production of autoantibodies against BP180/230, but increased Th2, eosinophil and coagulation cascade activity may be contributory.
- 29 July 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (5) , 463-467
Open AccessSerum Biomarkers in Bullous Pemphigoid: A Systematic Review
Introduction: Bullous pemphigoid (BP) is the most common type of subepidermal blistering disease, usually observed in the elderly population, with a mean age of presentation between 66 and 83 years. BP is a psychosocially ladened disease, with many patients experiencing negative body image, social isolation, and depression. The identification and validation of biomarkers in BP may further the understanding of disease pathogenesis, provide objective measures in assessing efficacy in clinical trials, and identify new targets for targeted therapy. Methods/Results: Two databases (Medline and Embase) were searched from database inception to September 2023. All published articles reporting on biomarker levels of BP patients in serum compared to healthy controls were included. A total of 877 unique articles were identified, resulting in the inclusion of 62 case-control studies reporting on a total of 1837 patients and 140 unique biomarkers. Biomarkers were categorized into T-cell mediated, B-cell mediated, innate immune system, and coagulation cascade pathway. The most notable biomarkers identified include increases in anti-BP180/230 immunoglobulin (Ig)G/E, total IgE, TNF-α, B-cell activating factor, interleukin-31, eosinophil cationic protein, MMP-9, and coagulation cascade biomarker levels. The results of this review provide the greatest support for a role of anti-BP180/230 autoantibodies, Th2 cells, eosinophils, and the coagulation cascade in the pathogenesis of BP. Conclusions: The pathogenesis of BP has an underlying autoimmune etiology centred around the production of autoantibodies against BP180/230, but increased Th2, eosinophil and coagulation cascade activity may be contributory.
- Open Access
- 29 July 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (5) , 458-462
Biomarkers in Pemphigus Vulgaris: A Systematic Review
Introduction: Pemphigus vulgaris (PV) is a rare intraepidermal blistering disease that is potentially life-threatening due to risk of infection and failure of skin barrier function. The identification of biomarkers has the potential to provide diagnostic utility and identify new therapeutic targets. The objective of this systematic review is to identify all potentially relevant PV biomarkers, categorize them, and identify trends to determine the involvement of T-cell-mediated, B-cell-1mediated, and innate immune-mediated pathways in PV pathogenesis. Methods/Results: Medline and Embase databases were searched according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, resulting in the inclusion of 66 studies that reported on a total of 2463 patients and 146 unique biomarkers. Biomarkers were categorized into T-cell-mediated, B-cell-mediated, and innate immune system pathways. The most notable biomarkers trends include elevations in IL-4, IL-6, IL-17A, anti-Dsg1/3 autoantibodies, and a reduction in Treg cells and FOXP3. Conclusion: The results of this review support current theories of PV pathogenesis, with increased Th2 activity, increased Th17 activity, decreased Treg activity, and production of anti-Dsg1/3 autoantibodies being observed. Targeting of IL-4 and IL-6 may provide therapeutic benefit. However, more research is required to validate biomarkers for clinical utility and assess viability as therapeutic targets.
- 29 July 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (5) , 458-462
Open AccessBiomarkers in Pemphigus Vulgaris: A Systematic Review
Introduction: Pemphigus vulgaris (PV) is a rare intraepidermal blistering disease that is potentially life-threatening due to risk of infection and failure of skin barrier function. The identification of biomarkers has the potential to provide diagnostic utility and identify new therapeutic targets. The objective of this systematic review is to identify all potentially relevant PV biomarkers, categorize them, and identify trends to determine the involvement of T-cell-mediated, B-cell-1mediated, and innate immune-mediated pathways in PV pathogenesis. Methods/Results: Medline and Embase databases were searched according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, resulting in the inclusion of 66 studies that reported on a total of 2463 patients and 146 unique biomarkers. Biomarkers were categorized into T-cell-mediated, B-cell-mediated, and innate immune system pathways. The most notable biomarkers trends include elevations in IL-4, IL-6, IL-17A, anti-Dsg1/3 autoantibodies, and a reduction in Treg cells and FOXP3. Conclusion: The results of this review support current theories of PV pathogenesis, with increased Th2 activity, increased Th17 activity, decreased Treg activity, and production of anti-Dsg1/3 autoantibodies being observed. Targeting of IL-4 and IL-6 may provide therapeutic benefit. However, more research is required to validate biomarkers for clinical utility and assess viability as therapeutic targets.
- Open Access
- 28 May 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (4) , 352-359
Efficacy of Treatments in Reducing Inflammatory Lesion Count in Rosacea: A Systematic Review
Introduction: Rosacea is a chronic inflammatory skin condition affecting approximately 5.5% of the global population. Patients present heterogeneously with a mix of features in the central facial region, of which papules and pustules are considered to be a major feature. The identification of effective treatments for reducing inflammatory lesions in rosacea can alleviate the psychosocial burden that many rosacea patients experience, including reduced self-esteem, anxiety, and social withdrawal. The objective of this systematic review is to determine the effectiveness of topical and systemic therapies in reducing lesion count in rosacea patients. Methods/Results: Medline, Embase, and Cochrane CENTRAL databases were searched, resulting in the inclusion of 43 clinical trials reporting on a total of 18,347 rosacea patients. The most well-studied treatments include ivermectin, metronidazole, azelaic acid, minocycline, and doxycycline. Oral isotretinoin was the most effective treatment in reducing inflammatory lesions and may be recommended for severe recalcitrant cases of rosacea. Conclusions: Several topical and systemic therapies have demonstrated efficacy in reducing inflammatory lesion count in rosacea patients, with mechanisms of action centred around suppressing inflammation and killing Demodex folliculorum mites. Additional research is required to determine effective combination therapies in rosacea.
- 28 May 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (4) , 352-359
Open AccessEfficacy of Treatments in Reducing Inflammatory Lesion Count in Rosacea: A Systematic Review
Introduction: Rosacea is a chronic inflammatory skin condition affecting approximately 5.5% of the global population. Patients present heterogeneously with a mix of features in the central facial region, of which papules and pustules are considered to be a major feature. The identification of effective treatments for reducing inflammatory lesions in rosacea can alleviate the psychosocial burden that many rosacea patients experience, including reduced self-esteem, anxiety, and social withdrawal. The objective of this systematic review is to determine the effectiveness of topical and systemic therapies in reducing lesion count in rosacea patients. Methods/Results: Medline, Embase, and Cochrane CENTRAL databases were searched, resulting in the inclusion of 43 clinical trials reporting on a total of 18,347 rosacea patients. The most well-studied treatments include ivermectin, metronidazole, azelaic acid, minocycline, and doxycycline. Oral isotretinoin was the most effective treatment in reducing inflammatory lesions and may be recommended for severe recalcitrant cases of rosacea. Conclusions: Several topical and systemic therapies have demonstrated efficacy in reducing inflammatory lesion count in rosacea patients, with mechanisms of action centred around suppressing inflammation and killing Demodex folliculorum mites. Additional research is required to determine effective combination therapies in rosacea.
- Top Cited PapersOpen Access
- 7 March 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (2) , 178-189
Rosacea: Pathogenesis and Therapeutic Correlates
Rosacea is a chronic inflammatory condition of which there is no cure. The pathogenesis of rosacea is likely multifactorial, involving genetic and environmental contributions. Current understanding suggests that pro-inflammatory pathways involving cathelicidins and inflammasome complexes are central to rosacea pathogenesis. Common rosacea triggers modulate these pathways in a complex manner, which may contribute to the varying severity and clinical presentations of rosacea. Established and emerging rosacea treatments may owe their efficacy to their ability to target different players in these pro-inflammatory pathways. Improving our molecular understanding of rosacea will guide the development of new therapies and the use of combination therapies.
- 7 March 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (2) , 178-189
Top Cited PapersOpen AccessRosacea: Pathogenesis and Therapeutic Correlates
Rosacea is a chronic inflammatory condition of which there is no cure. The pathogenesis of rosacea is likely multifactorial, involving genetic and environmental contributions. Current understanding suggests that pro-inflammatory pathways involving cathelicidins and inflammasome complexes are central to rosacea pathogenesis. Common rosacea triggers modulate these pathways in a complex manner, which may contribute to the varying severity and clinical presentations of rosacea. Established and emerging rosacea treatments may owe their efficacy to their ability to target different players in these pro-inflammatory pathways. Improving our molecular understanding of rosacea will guide the development of new therapies and the use of combination therapies.
- 27 March 2020
- Published by Springer Nature
- p. 35-52
The Use of Antiseptic and Antibacterial Agents on Wounds and the Skin
- 27 March 2020
- Published by Springer Nature
- p. 35-52
The Use of Antiseptic and Antibacterial Agents on Wounds and the Skin
- 1 October 2017
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
- Vol. 30 (10) , 438-450
Update: Topical Antimicrobial Agents for Chronic Wounds
GENERAL PURPOSE: To provide information on the use of topical antimicrobial agents for the treatment of chronic wounds. TARGET AUDIENCE: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care. LEARNING OBJECTIVES/OUTCOMES: After participating in this educational activity, the participant should be better able to: 1. Examine features of wounds and wound healing as well as the purpose of specific antimicrobial agents. 2. Identify potential therapeutic and adverse effects of specific topical antimicrobial agents for the treatment of chronic wounds. Bacteria can delay or prevent healing in the surface compartment of a chronic wound or invade the deep and surrounding structures. This article focuses on the superficial compartment and the appropriate use of topical antimicrobial therapies. The authors have reviewed the published evidence for the last 5 years (2012–2017) and extrapolated findings to clinical practice with critical appraisal and synthesis of the recent literature with expert opinion, patient-centered concerns, and healthcare systems perspectives. Summary evidence tables for commonly used topical antimicrobials are included.
- 1 October 2017
- Published by Wolters Kluwer Health in Advances in Skin & Wound Care
- Vol. 30 (10) , 438-450
Update: Topical Antimicrobial Agents for Chronic Wounds
GENERAL PURPOSE: To provide information on the use of topical antimicrobial agents for the treatment of chronic wounds. TARGET AUDIENCE: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care. LEARNING OBJECTIVES/OUTCOMES: After participating in this educational activity, the participant should be better able to: 1. Examine features of wounds and wound healing as well as the purpose of specific antimicrobial agents. 2. Identify potential therapeutic and adverse effects of specific topical antimicrobial agents for the treatment of chronic wounds. Bacteria can delay or prevent healing in the surface compartment of a chronic wound or invade the deep and surrounding structures. This article focuses on the superficial compartment and the appropriate use of topical antimicrobial therapies. The authors have reviewed the published evidence for the last 5 years (2012–2017) and extrapolated findings to clinical practice with critical appraisal and synthesis of the recent literature with expert opinion, patient-centered concerns, and healthcare systems perspectives. Summary evidence tables for commonly used topical antimicrobials are included.
- Open Access
- 16 October 2016
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2016, 1-4
Generational Expression of Muir-Torre Syndrome in a Canadian Family
Muir-Torre syndrome (MTS) is a rare autosomal dominant inherited genodermatosis that is considered to be a phenotypic subtype of hereditary nonpolyposis colorectal cancer (HNPCC), commonly referred to as Lynch syndrome. We describe the clinical course of a 57-year-old female patient with MTS. She has a confirmedHMSH2mutation. Recently she presented with two nodular lesions. Histologic examination confirmed these lesions to be sebaceous neoplasms. The patient has a history of endometrial and colorectal adenocarcinoma as well as several nonspecific sebaceous lesions throughout her life. She has a confirmed extensive family history of MTS with both male and female family members harbouring eitherHMLH1orHSMH2mutations. Affected relatives have presented at different ages throughout their lives with cutaneous neoplasms and visceral malignancies, including malignancies rarely associated with MTS. MTS presents a diagnostic challenge for clinicians. The case demonstrates that the management of MTS, a potentially underreported syndrome, requires a multiprofessional approach incorporating vigilance, screening, and expert knowledge for successful diagnosis and potentially improved prognosis for patients and their families. The case also demonstrates the varied heritability of MTS and prompts the question of how MTS is expressed in succeeding generations.
- 16 October 2016
- Published by Wiley in Case Reports in Dermatological Medicine
- Vol. 2016, 1-4
Open AccessGenerational Expression of Muir-Torre Syndrome in a Canadian Family
Muir-Torre syndrome (MTS) is a rare autosomal dominant inherited genodermatosis that is considered to be a phenotypic subtype of hereditary nonpolyposis colorectal cancer (HNPCC), commonly referred to as Lynch syndrome. We describe the clinical course of a 57-year-old female patient with MTS. She has a confirmedHMSH2mutation. Recently she presented with two nodular lesions. Histologic examination confirmed these lesions to be sebaceous neoplasms. The patient has a history of endometrial and colorectal adenocarcinoma as well as several nonspecific sebaceous lesions throughout her life. She has a confirmed extensive family history of MTS with both male and female family members harbouring eitherHMLH1orHSMH2mutations. Affected relatives have presented at different ages throughout their lives with cutaneous neoplasms and visceral malignancies, including malignancies rarely associated with MTS. MTS presents a diagnostic challenge for clinicians. The case demonstrates that the management of MTS, a potentially underreported syndrome, requires a multiprofessional approach incorporating vigilance, screening, and expert knowledge for successful diagnosis and potentially improved prognosis for patients and their families. The case also demonstrates the varied heritability of MTS and prompts the question of how MTS is expressed in succeeding generations.
- 10 August 2015
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 187 (16) , 1235
Hidradenitis suppurativa
- 10 August 2015
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 187 (16) , 1235
Hidradenitis suppurativa